Skip to main content
Premium Trial:

Request an Annual Quote

Bio-Techne to Acquire Single-Cell Sorting Firm Namocell

NEW YORK – Bio-Techne said on Wednesday that it has agreed to acquire single-cell sorting and dispensing firm Namocell.

Financial and other terms of the deal were not disclosed. The acquisition is expected to close in the first quarter of Bio-Techne’s fiscal year 2023. 

Namocell, founded in 2014 and based in Mountain View, California, currently offers multiple instruments, including Pala, a two-laser system with up to 11 fluorescent detection channels, and Hana, a single-laser system with two fluorescent detection channels. The platforms both use Namocell's proprietary technology, which combines microfluidics, flow cytometry, and liquid dispensing, to deliver single cells from samples to plates. So far, the firm has installed nearly 200 instruments, Bio-Techne said. 

The acquisition will complement Bio-Techne's cell and gene therapy business, and the firm anticipates "significant commercial synergies as we leverage our existing analytical tools sales force to penetrate this market opportunity," Bio-Techne President and CEO Chuck Kummeth said in a statement.

"Emerging technologies in cell-based research as well as next-generation therapeutics have created a need for fast, reliable, easy-to-use, and gentle cell sorting," he added. "Namocell's instruments offer unparalleled performance advantages over traditional flow cytometry and manual techniques and we anticipate continued traction with its leading portfolio of cell sorting technologies."

Namocell CEO Junyu Lin said in a statement that "Bio-Techne's global reach and strategic deployment in cell and gene therapy will enable Namocell to accelerate its penetration into the global markets, particularly in cell engineering and cell therapy applications, our biggest and fastest growing sectors."

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.